

Resource Summary Report

Generated by [NIF](#) on Aug 14, 2026

Human TIM-3 APC-conjugated Antibody

RRID:AB_1964725

Type: Antibody

Proper Citation

R and D Systems Cat# FAB2365A, RRID:AB_1964725

Antibody Information

URL: http://antibodyregistry.org/AB_1964725

Proper Citation: R and D Systems Cat# FAB2365A, RRID:AB_1964725

Target Antigen: TIM-3

Host Organism: Rat

Clonality: monoclonal

Comments: Applications: Flow Cytometry

Antibody Name: Human TIM-3 APC-conjugated Antibody

Description: This monoclonal targets TIM-3

Target Organism: Human

Clone ID: 344823

Antibody ID: AB_1964725

Vendor: R and D Systems

Catalog Number: FAB2365A

Record Creation Time: 20250820T011140+0000

Record Last Update: 20250820T101642+0000

Ratings and Alerts

No rating or validation information has been found for Human TIM-3 APC-conjugated Antibody.

No alerts have been found for Human TIM-3 APC-conjugated Antibody.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 6 mentions in open access literature.

Listed below are recent publications. The full list is available at [NIF](#) .

Guercio BJ, et al. (2026) Neoadjuvant Nivolumab with or without Ipilimumab for Cisplatin-Ineligible Patients with Muscle-Invasive Bladder Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research, 32(8), 1434.

Rosenbaum E, et al. (2026) Association of Circulating T Cell and Tumor Microenvironment Profiles with Immune Checkpoint Blockade Outcomes in Sarcoma. Clinical cancer research : an official journal of the American Association for Cancer Research, 32(9), 1777.

Chiffelle J, et al. (2024) Tumor-reactive T^{reg} cell clonotype dynamics underlying clinical response to TIL therapy in melanoma. Immunity, 57(10), 2466.

Comen E, et al. (2024) Preoperative immune checkpoint inhibition and cryoablation in early-stage breast cancer. iScience, 27(2), 108880.

Gannon PO, et al. (2020) Development of an optimized closed and semi-automatic protocol for Good Manufacturing Practice manufacturing of tumor-infiltrating lymphocytes in a hospital environment. Cytotherapy, 22(12), 780.

Naing A, et al. (2018) PEGylated IL-10 (Pegilodecakin) Induces Systemic Immune Activation, CD8⁺ T Cell Invigoration and Polyclonal T Cell Expansion in Cancer Patients. Cancer cell, 34(5), 775.